ARIDIS PHARMACEU(ARDS) - 2023 Q2 - Quarterly Report

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2641188 (State or other jurisdiction of incorporation or org ...